{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:14:18Z","timestamp":1778591658351,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Institute of Health","award":["R37CA278744"],"award-info":[{"award-number":["R37CA278744"]}]},{"name":"NIH NCI U54 Metastasis Network Seed Grant","award":["U54CA261717"],"award-info":[{"award-number":["U54CA261717"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"DOI":"10.1186\/s41181-026-00451-1","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T11:05:59Z","timestamp":1777719959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["MUC1-targeting small peptide radiopharmaceuticals for breast cancer"],"prefix":"10.1186","volume":"11","author":[{"given":"Rim","family":"Malek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeleine","family":"Landry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1718-3272","authenticated-orcid":false,"given":"Corinne","family":"Beinat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"issue":"1","key":"451_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s41181-021-00127-y","volume":"6","author":"I Al Jammaz","year":"2021","unstructured":"Al Jammaz I, Al-Otaibi B, Al-Malki Y, Abousekhrah A, Okarvi SM. Fast Fluorine-18 labeling and preclinical evaluation of novel Mucin1 and its Folate hybrid peptide conjugate for targeting breast carcinoma. EJNMMI Radiopharm Chem. 2021;6(1):12.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"1","key":"451_CR2","first-page":"2329676","volume":"2021","author":"S Alhabardi","year":"2021","unstructured":"Alhabardi S, Radwan H, Alotaibi B, Almalki Y, Elzayat E, Shinwari Z, et al. Synthesis, radiolabeling, and biological evaluation of 68Ga-Mucin1 and its folate hybrid peptide conjugates for the diagnosis of ovarian cancer. J Chem. 2021;2021(1):2329676.","journal-title":"J Chem"},{"issue":"23","key":"451_CR3","doi-asserted-by":"publisher","first-page":"4475","DOI":"10.1007\/s00018-015-2014-z","volume":"72","author":"V Apostolopoulos","year":"2015","unstructured":"Apostolopoulos V, Stojanovska L, Gargosky SE. MUC1 (CD227): a multi-tasked molecule. Cell Mol Life Sci. 2015;72(23):4475\u2013500.","journal-title":"Cell Mol Life Sci"},{"issue":"10265","key":"451_CR4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817\u201328.","journal-title":"Lancet"},{"issue":"1","key":"451_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1021\/bc025542f","volume":"14","author":"J Fichna","year":"2003","unstructured":"Fichna J, Janecka A. Synthesis of target-specific radiolabeled peptides for diagnostic imaging. Bioconjug Chem. 2003;14(1):3\u201317.","journal-title":"Bioconjug Chem"},{"issue":"2","key":"451_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.clbc.2012.09.016","volume":"13","author":"SK Ghosh","year":"2013","unstructured":"Ghosh SK, Pantazopoulos P, Medarova Z, Moore A. Expression of underglycosylated MUC1 antigen in cancerous and adjacent normal breast tissues. Clin Breast Cancer. 2013;13(2):109\u201318.","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"451_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast cancer. Nat Rev Dis Primers. 2019;5(1):1\u201331.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"451_CR8","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1002\/pro.5560031206","volume":"3","author":"EG Hutchinson","year":"1994","unstructured":"Hutchinson EG, Thornton JM. A revised set of potentials for \u03b2-turn formation in proteins. Protein Sci. 1994;3(12):2207\u201316.","journal-title":"Protein Sci"},{"issue":"2","key":"451_CR9","first-page":"801","volume":"41","author":"X Jing","year":"2019","unstructured":"Jing X, Liang H, Hao C, Yang X, Cui X. Overexpression of MUC1 predicts poor prognosis in patients with breast cancer. Oncol Rep. 2019;41(2):801\u201310.","journal-title":"Oncol Rep"},{"issue":"15","key":"451_CR10","doi-asserted-by":"publisher","first-page":"6946","DOI":"10.7150\/thno.38236","volume":"10","author":"VJ Kelly","year":"2020","unstructured":"Kelly VJ, Wu S-T, Gottumukkala V, Coelho R, Palmer K, Nair S, et al. Preclinical evaluation of an 111In\/225Ac theranostic targeting transformed MUC1 for triple negative breast cancer. Theranostics. 2020;10(15):6946\u201358.","journal-title":"Theranostics"},{"issue":"8","key":"451_CR12","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1021\/bc300103t","volume":"23","author":"D Mueller","year":"2012","unstructured":"Mueller D, Klette I, Baum RP, Gottschaldt M, Schultz MK, Breeman WAP. Simplified NaCl based 68Ga concentration and labeling procedure for rapid synthesis of 68Ga radiopharmaceuticals in high radiochemical purity. Bioconjug Chem. 2012;23(8):1712\u20137.","journal-title":"Bioconjug Chem"},{"issue":"6","key":"451_CR13","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.molmed.2014.02.007","volume":"20","author":"S Nath","year":"2014","unstructured":"Nath S, Mukherjee P. MUC1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 2014;20(6):332\u201342.","journal-title":"Trends Mol Med"},{"issue":"7","key":"451_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.nucmedbio.2016.03.006","volume":"43","author":"SM Okarvi","year":"2016","unstructured":"Okarvi SM, Al Jammaz I. Preparation and evaluation of the tumor-specific antigen-derived synthetic mucin 1 peptide: a potential candidate for the targeting of breast carcinoma. Nucl Med Biol. 2016;43(7):403\u20139.","journal-title":"Nucl Med Biol"},{"issue":"17","key":"451_CR15","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.3390\/molecules24173142","volume":"24","author":"SM Okarvi","year":"2019","unstructured":"Okarvi SM, AlJammaz I. Development of the tumor-specific antigen-derived synthetic peptides as potential candidates for targeting breast and other possible human carcinomas. Molecules. 2019;24(17):3142.","journal-title":"Molecules"},{"issue":"4","key":"451_CR16","first-page":"1399","volume":"29","author":"SM Okarvi","year":"2009","unstructured":"Okarvi SM, Jammaz IA, Design. Synthesis, radiolabeling and in vitro and in vivo characterization of tumor-antigen- and antibody-derived peptides for the detection of breast cancer. Anticancer Res. 2009;29(4):1399\u2013409.","journal-title":"Anticancer Res"},{"key":"451_CR17","doi-asserted-by":"crossref","unstructured":"Orrantia-Borunda E, Anchondo-Nu\u00f1ez P, Acu\u00f1a-Aguilar LE, G\u00f3mez-Valles FO, Ram\u00edrez-Valdespino CA. Subtypes of breast cancer. In: Mayrovitz HN, editor. Breast cancer [Internet]. Brisbane (AU): Exon Publications; 2022 [cited 2024 Dec 23]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK583808\/.","DOI":"10.36255\/exon-publications-breast-cancer-subtypes"},{"issue":"22","key":"451_CR18","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108\u201321.","journal-title":"N Engl J Med"},{"issue":"4","key":"451_CR19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.4161\/cbt.6.4.4201","volume":"6","author":"R Singh","year":"2007","unstructured":"Singh R, Bandyopadhyay D. MUC1: a target molecule for cancer therapy. Cancer Biol Ther. 2007;6(4):481\u20136.","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"451_CR20","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer. J Clin. 2021;71(3):209\u201349.","journal-title":"J Clin"},{"issue":"5","key":"451_CR11","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/(SICI)1097-0215(20000601)86:5<702::AID-IJC16>3.0.CO;2-1","volume":"86","author":"S von Mensdorff-Pouilly","year":"2000","unstructured":"von Mensdorff-Pouilly S, Petrakou E, Kenemans P, van Uffelen K, Verstraeten AA, Snijdewint FGM, et al. Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int J Cancer. 2000;86(5):702\u201312.","journal-title":"Int J Cancer"},{"key":"451_CR21","doi-asserted-by":"publisher","unstructured":"Yi H, Li Y, Tan Y, Fu S, Tang F, Deng X. Immune checkpoint inhibition for triple-negative breast cancer: current landscape and future perspectives. Front Oncol. [Internet]. Frontiers; 2021 May 19 [cited 2024 Dec 23];11. Available from: https:\/\/www.frontiersin.org\/journals\/oncology\/articles\/https:\/\/doi.org\/10.3389\/fonc.2021.648139\/full","DOI":"10.3389\/fonc.2021.648139\/full"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-026-00451-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00451-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-026-00451-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:41:14Z","timestamp":1778589674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41181-026-00451-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["451"],"URL":"https:\/\/doi.org\/10.1186\/s41181-026-00451-1","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were realized following the guidelines for the Care and Use of Laboratory Animals of Stanford University and approved by The Administrative Panel on Laboratory and Animal Care (APLAC)\/Institutional Animal Care and Use Committee (IACUC) of Stanford University. This research does not involve human subjects and this is therefore not applicable. No client owned animals were used in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent for participation"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}